Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19^{[1][2][3][4][5]}.

Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells^[1].
Deferoxamine mesylate (100 µM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels^[2].
Deferoxamine mesylate (5, 10, 25, 50, 100 µM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs^[3].
Deferoxamine mesylate (5, 10, 25, 50, 100 µM; 7 days) induces apoptosis of MSCs^[3].
Deferoxamine mesylate (10 µM ; 3 days) influencs the expression of adhesion proteins on MSCs^[3].
Deferoxamine mesylate (100 µM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:MEFs cellsConcentration:1 mMIncubation Time:16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)Result:Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions.Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

Deferoxamine mesylate (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice^[1].
Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model)[1].Dosage:560.68 mg/per (10 uL of 1 mM)Administration:Drip-on; once daily for 21 days.Result:Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.

NCT NumberSponsorConditionStart DatePhaseNCT00600938Novartis Pharmaceuticals|NovartisTransfusional Iron Overload|Transfusional HemosiderosisNovember 2007Phase 2NCT03137966Karolinska University HospitalDiabetic Foot UlcerDecember 30, 2022Phase 2NCT01254227Novartis Pharmaceuticals|NovartisCardiac Iron OverloadJanuary 2011Phase 2

656.79

Solid

C₂₆H₅₂N₆O₁₁S

138-14-7

甲磺酸去铁胺；去铁胺甲磺酸酯；甲磺酸去铁敏；甲磺酸除铁灵

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

In Vitro: 

H₂O : 250 mg/mL (380.64 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量1 mg5 mg10 mg1 mM1.5226 mL7.6128 mL15.2256 mL5 mM0.3045 mL1.5226 mL3.0451 mL10 mM0.1523 mL0.7613 mL1.5226 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 请依序添加每种溶剂： PBS

  Solubility: 5.56 mg/mL (8.47 mM); Clear solution; Need ultrasonic